Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) EBIT: 2023-2025

Historic EBIT for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$2.3 million.

  • BioLineRx's EBIT rose 60.11% to -$2.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$14.5 million, marking a year-over-year increase of 65.06%. This contributed to the annual value of -$20.4 million for FY2024, which is 58.93% up from last year.
  • Per BioLineRx's latest filing, its EBIT stood at -$2.3 million for Q2 2025, which was up 3.68% from -$2.4 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's EBIT ranged from a high of -$2.3 million in Q2 2025 and a low of -$18.6 million during Q4 2023.
  • Its 3-year average for EBIT is -$7.5 million, with a median of -$5.6 million in 2024.
  • Data for BioLineRx's EBIT shows a peak YoY soared of 76.16% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows BioLineRx's EBIT stood at -$18.6 million in 2023, then spiked by 76.16% to -$4.4 million in 2024, then spiked by 60.11% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q2 2025, -$2.4 million for Q1 2025, and -$4.4 million during Q4 2024.